Citadel Securities LLC recently announced the acquisition of new stake in Novabay Pharmaceuticals Inc (AMEX:NBY). This fresh investment now brings its stake to 1.30% valued currently at $25544.0. In addition, Renaissance Technologies LLC raised its holdings by 13900.0 to 58823.0 shares.
With over 19.56 million Novabay Pharmaceuticals Inc (NBY) shares trading Tuesday and a closing price of $0.19 on the day, the dollar volume was approximately $3.72 million. The shares have shown a negative half year performance of -73.17% and its price on 01/09/24 gained nearly 4.94%. Currently, there are 6.53M common shares owned by the public and among those 6.37M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 5,148 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Novabay Pharmaceuticals Inc are Fidelity Extended Market Index Fu, Vanguard Extended Market Index Fu, and Fidelity Series Total Market Inde. Fidelity Extended Market Index Fu owns 23861.0 shares of the company’s stock, all valued at over $7158.0. Fidelity Series Total Market Inde now owns shares totaling to 0.02% of the shares outstanding.
Shares of Novabay Pharmaceuticals Inc (AMEX: NBY) opened at $0.20, up $0.02 from a prior closing price of $0.18. However, the script later moved the day high at 0.2388, up 4.94%. The company’s stock has a 5-day price change of -2.93% and -54.45% over the past three months. NBY shares are trading -7.40% year to date (YTD), with the 12-month market performance down to -90.56% lower. It has a 12-month low price of $0.15 and touched a high of $2.65 over the same period. NBY has an average intraday trading volume of 306.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -19.41%, -34.28%, and -72.19% respectively.
Institutional ownership of Novabay Pharmaceuticals Inc (AMEX: NBY) shares accounts for 3.95% of the company’s 6.53M shares outstanding. Mutual fund holders own 0.54%, while other institutional holders and individual stakeholders account for 3.41% and 0.13% respectively.
It has a market capitalization of $1.23M and a beta (3y monthly) value of 2.03. The earnings-per-share (ttm) stands at -$6.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.97% over the week and 11.06% over the month.
Analysts forecast that Novabay Pharmaceuticals Inc (NBY) will achieve an EPS of -$0.3 for the current quarter, -$0.22 for the next quarter and -$0.64 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.3 while analysts give the company a high EPS estimate of -$0.3. Comparatively, EPS for the current quarter was -$0.78 a year ago. Earnings per share for the fiscal year are expected to increase by 77.13%, and 68.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Novabay Pharmaceuticals Inc (NBY) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NBY, a number of firms have released research notes about the stock. Ladenburg Thalmann stated their Buy rating for the stock in a research note on September 18, 2019, with the firm’s price target at $1.10.
